JSPR insider transaction filings
Jasper Therapeutics, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-04. Screen JSPR transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 7 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 8.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Crutcher Patrick J — Director | 2 | — | — | 3 |
| EMSTER KURT VON — Director | 1 | — | — | 1 |
| Lucas Svetlana — Director | 1 | — | — | 1 |
| Ros Matthew E — Chief Operating Officer | 1 | — | — | 1 |
| Shizuru Judith Anne — Director | 1 | — | — | 1 |
| WIGGANS THOMAS G — Director | 1 | — | — | 1 |
Recent Form 4 filings — Jasper Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-04 | 4 | Shizuru Judith Anne — Director | Grant/award (A): 7,500 (derivative) @ $0 | EDGAR |
| 2026-08-04 | 4 | EMSTER KURT VON — Director | Grant/award (A): 7,500 (derivative) @ $0 | EDGAR |
| 2026-08-04 | 4 | Crutcher Patrick J — Director | Grant/award (A): 7,500 (derivative) @ $0 | EDGAR |
| 2026-08-04 | 4 | Lucas Svetlana — Director | Grant/award (A): 7,500 (derivative) @ $0 | EDGAR |
| 2026-08-04 | 4 | WIGGANS THOMAS G — Director | Grant/award (A): 7,500 (derivative) @ $0 | EDGAR |
| 2026-07-22 | 4 | Ros Matthew E — Chief Operating Officer | Purchase (P): 881 (derivative) | EDGAR |
| 2026-07-20 | 4 | Crutcher Patrick J — Director | Grant/award (A): 15,000 (derivative) @ $0 · Purchase (P): 888 (derivative) | EDGAR |
| 2026-02-10 | 4 | Mahal Jeetinder Singh — CEO and President, Director | Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Mahal Jeetinder Singh — Chief Operating Officer | Grant/award (A): 90,000 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | CROSS HERB — Chief Financial Officer | Grant/award (A): 90,000 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | MARTELL RON — President, CEO and Director, Director | Grant/award (A): 234,000 (derivative) @ $0 | EDGAR |
| 2025-09-24 | 4 | Shizuru Judith Anne — Director | Purchase (P): 41,000 @ $2.43 · Purchase (P): 41,000 (derivative) | EDGAR |
| 2025-09-24 | 4 | Lucas Svetlana — Director | Purchase (P): 20,000 @ $2.43 · Purchase (P): 20,000 (derivative) | EDGAR |
| 2025-09-24 | 4 | WIGGANS THOMAS G — Director | Purchase (P): 41,000 @ $2.43 · Purchase (P): 41,000 (derivative) | EDGAR |
| 2025-09-24 | 4 | MARTELL RON — President and CEO, Director | Purchase (P): 41,000 @ $2.43 · Purchase (P): 41,000 (derivative) | EDGAR |
| 2025-07-03 | 4 | Brun Scott C. — Director | Grant/award (A): 7,500 (derivative) @ $0 | EDGAR |
| 2025-07-03 | 4 | Shizuru Judith Anne — Director | Grant/award (A): 7,500 (derivative) @ $0 | EDGAR |
| 2025-07-03 | 4 | Kapoor Vishal — Director | Grant/award (A): 7,500 (derivative) @ $0 | EDGAR |
| 2025-07-03 | 4 | Nolet Chris — Director | Grant/award (A): 7,500 (derivative) @ $0 | EDGAR |
| 2025-07-03 | 4 | Lucas Svetlana — Director | Grant/award (A): 7,500 (derivative) @ $0 | EDGAR |
| 2025-07-03 | 4 | EMSTER KURT VON — Director | Grant/award (A): 7,500 (derivative) @ $0 | EDGAR |
| 2025-07-03 | 4 | WIGGANS THOMAS G — Director | Grant/award (A): 7,500 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Mahal Jeetinder Singh — Chief Operating Officer | Grant/award (A): 90,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Tucker Edwin Jonathan — Chief Medical Officer | Grant/award (A): 90,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | CROSS HERB — Chief Financial Officer | Grant/award (A): 90,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | MARTELL RON — President and CEO, Director | Grant/award (A): 234,000 (derivative) @ $0 | EDGAR |
| 2025-02-18 | 4 | Mahal Jeetinder Singh — Chief Operating Officer | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-02-18 | 4 | Tucker Edwin Jonathan — Chief Medical Officer | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-02-18 | 4 | CROSS HERB — Chief Financial Officer | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-02-18 | 4 | MARTELL RON — President, CEO and Director, Director | Grant/award (A): 130,000 (derivative) @ $0 | EDGAR |
| 2024-12-12 | 4 | Mahal Jeetinder Singh — Chief Operating Officer | Option exercise (M): 900 @ $7.10 · Sale (S): 900 @ $22.11 · Option exercise (M): 900 (derivative) @ $0 | EDGAR |
| 2024-09-12 | 4 | Mahal Jeetinder Singh — Chief Operating Officer | Option exercise (M): 900 @ $7.10 · Sale (S): 900 @ $21.23 · Option exercise (M): 900 (derivative) @ $0 | EDGAR |
| 2024-06-20 | 4 | Lucas Svetlana — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2024-06-12 | 4 | Mahal Jeetinder Singh — Chief Operating Officer | Option exercise (M): 900 @ $7.10 · Sale (S): 900 @ $24.16 · Option exercise (M): 900 (derivative) @ $0 | EDGAR |
| 2024-06-12 | 4 | MARTELL RON — President, CEO and Director, Director | Grant/award (A): 10,000 (derivative) @ $0 · Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | Tucker Edwin Jonathan — Chief Medical Officer | Grant/award (A): 400 @ $4.17 | EDGAR |
| 2024-06-10 | 4 | French Anna Louise — Director | Grant/award (A): 7,500 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | Shizuru Judith Anne — Director | Grant/award (A): 7,500 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | Kapoor Vishal — Director | Grant/award (A): 7,500 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | Brun Scott C. — Director | Grant/award (A): 7,500 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | Nolet Chris — Director | Grant/award (A): 7,500 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | EMSTER KURT VON — Director | Grant/award (A): 7,500 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | WIGGANS THOMAS G — Director | Grant/award (A): 7,500 (derivative) @ $0 | EDGAR |
| 2024-03-12 | 4 | Mahal Jeetinder Singh — Chief Operating Officer | Option exercise (M): 900 @ $7.10 · Sale (S): 900 @ $26.44 · Option exercise (M): 900 (derivative) @ $0 | EDGAR |
| 2024-02-20 | 4 | Mahal Jeetinder Singh — Chief Operating Officer | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2024-02-20 | 4 | Tucker Edwin Jonathan — Chief Medical Officer | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2024-02-20 | 4 | CROSS HERB — Chief Financial Officer | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2024-02-20 | 4 | MARTELL RON — President, CEO and Director, Director | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2024-02-12 | 4 | Carlyle Group Inc. Carlyle Holdings I GP Inc. — 10% owner Carlyle Holdings I GP Sub L.L.C. — 10% owner Carlyle Holdings I L.P. — 10% owner CG Subsidiary Holdings L.L.C. — 10% owner TC Group, LLC — 10% owner Carlyle Investment Management LLC — 10% owner Carlyle Genesis UK LLC — 10% owner Abingworth LLP — 10% owner Abingworth Bioventures VII LP — 10% owner | Purchase (P): 190,000 @ $12.95 | EDGAR |
| 2024-02-09 | 4 | Velan Capital Investment Management LP — 10% owner Velan Capital Master Fund LP Avego Healthcare Capital, L.P. Velan Capital Holdings LLC Avego Healthcare Capital Holdings, LLC Avego Management LLC Velan Capital Management LLC — 10% owner VENKATARAMAN BALAJI — 10% owner Morgan Adam — 10% owner | Purchase (P): 350,000 @ $12.95 | EDGAR |
Recent 8-K events — Jasper Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-26 | 8-K | 1.01 — Entry into a Material Definitive Agreement | EDGAR |
| 2026-08-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-03 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-07-31 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-07-17 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 3.02 — Unregistered Sales of Equity Securities 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-16 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-09 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2026-06-01 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-21 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=JSPR returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →